Key result
Cardiopulmonary exercise testing after heart failure diagnosis is linked to ~42% lower 1-year mortality.
Why the study?
Whether cardiopulmonary exercise testing utilization and outcomes differ by race among patients with heart failure was unknown.
Does cardiopulmonary exercise testing (CPET) utilization associate with reduced mortality and heart failure hospitalization in adults with heart failure, and do these outcomes differ by race and ethnicity?
Cohort (n=807,379)
Yes
Does cardiopulmonary exercise testing (CPET) utilization associate with reduced mortality and heart failure hospitalization in adults with heart failure, and do these outcomes differ by race and ethnicity?
Hazard Ratio: 0.58 (95% CI 0.51–0.65)
p-value: p=<.001
CPET utilization is associated with improved mortality in certain racial/ethnic groups, but striking under-representation among minority patients highlights its use as a marker of inequity in access to advanced heart failure care.
Racial disparities in CPET use may persist despite Class I guidance; leaves open whether equity-focused strategies improve advanced HF therapy access.
Background and Aims Cardiopulmonary exercise testing (CPET) carries a Class I recommendation for advanced heart failure (HF) therapy candidacy. Whether CPET utilization and outcomes differ by race is unknown. Methods Using TriNetX, adults with HF (ICD-10 I50.x, 2010–23) were stratified by race/ethnicity and CPET receipt (CPT 94621) within 1 year of diagnosis. All-cause mortality and HF hospitalization were assessed at 1, 3, and 5 years after 1:1 propensity score matching for demographics, HF subtype, comorbidities, and guideline-directed medical therapy. Results Among 807 379 patients with HF (mean age 69.2 years, 46.2% female), 10 268 (1.27%) underwent CPET within 1 year. Utilization was 1.39% in White, 1.20% in Black, 0.69% in Hispanic, and 0.79% in Asian patients. After matching, 8355 pairs were analysed. CPET was associated with lower 1-year mortality in White (hazard ratio [HR] 0.58, 95% CI 0.51–0.65, P < .001) and Hispanic (HR 0.50, 0.25–0.98, P = .040) patients. Asian patients reached borderline significance at 5 years (HR 0.54, 0.29–1.00, P = .048). Black patients showed a non-significant trend (1-year HR 0.70, 0.39–1.24, P = .214). HF hospitalization was higher in White (1-year HR 1.18, 1.14–1.23, P < .001) and Asian (HR 1.73, 1.35–2.21, P < .001) CPET recipients, suggesting surveillance bias. Conclusions CPET utilization was associated with lower mortality in White and Hispanic patients, with borderline significance in Asian patients at 5 years and a non-significant trend in Black patients. These associations may reflect engagement with speciality HF care rather than testing itself. Minority patients were under-represented among CPET recipients, highlighting CPET access as a marker of inequity in advanced HF care.
No takes yet. Share an insight, caveat, or question.
Rice et al. (2026) conducted a cohort in Heart failure (n=807,379). Cardiopulmonary exercise testing (CPET) vs. No CPET was evaluated on 1-year all-cause mortality (White patients) (HR 0.58, 95% CI 0.51-0.65, p=<.001). Cardiopulmonary exercise testing within 1 year of heart failure diagnosis was associated with lower 1-year mortality in White (HR 0.58; 95% CI 0.51-0.65) and Hispanic patients.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: